Search PubMed⌕ Search

PubMed · 8634920

Potential problems with intermittent nitrate therapy.

Abstract

The organic nitrates continue to be widely used in clinical practice. The development of tolerance to these agents is now a well-recognized problem, although the use of a nitrate-free interval or compounds with specialized pharmacokinetic profiles can overcome this difficulty. Despite this success, prospective studies of intermittent transdermal nitroglycerin have suggested that the nitrate-free interval may be associated with two potential problems. The first is the development of crescendo angina during the nitrate-free interval. Such unstable clinical events occurring during the nitrate-free interval have been termed 'rebound angina' and are reminiscent of ischemic events reported in the munitions industry, where workers are exposed to high nitroglycerin concentrations. Intermittent nitroglycerin therapy has also been reported to cause a decrease in treadmill walking time to the onset of angina. This has been suggested from observations made in clinical trials of intermittent transdermal nitroglycerin therapy and was recently confirmed in a study from our laboratory, where the withdrawal of transdermal nitroglycerin was associated with a reduction in tread-mill exercise performance for a period of at least 6 h. Although rebound ischemia has been reported, this has not been a consistent observation in all clinical trials of intermittent nitrate therapy. Furthermore, it is not at all clear that a decrease in exercise tolerance, which would usually be occurring in the evening hours, is of any clinical importance. Nevertheless, these are potentially important observations that warrant further study and may provide further insight into the pathophysiology of nitrate tolerance.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J D Parker. 1996. Potential problems with intermittent nitrate therapy.. https://pubmed.ncbi.nlm.nih.gov/8634920/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗